Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma
By
Luisina María Solernó
Candela Llavona
Zahira Yasmine Saud
Mariana Carolina Onassis
María Florencia Gottardo
Martín Manuel Ledesma
Daniel Fernando Alonso
Juan Garona
July 1, 2026
Clinical Scorecard: Exploring the Efficacy of Combining Desmopressin and Bevacizumab as an Antiangiogenic Approach for Osteosarcoma Treatment
At a Glance
Category Detail
Condition Osteosarcoma (OSA) Key Mechanisms Inhibition of Vascular Endothelial Growth Factor A (VEGF-A) and modulation of angiogenesis through AVPR2 activation. Target Population Children and young adults with osteosarcoma. Care Setting Oncology, specifically in the context of targeted therapy for osteosarcoma.
Key Highlights
Desmopressin (dDAVP) enhances the efficacy of Bevacizumab (BEVA) in treating osteosarcoma. dDAVP significantly reduces pulmonary metastasis and vascularization in osteosarcoma models. Elevated AVPR2 expression correlates with improved survival in osteosarcoma patients. Combined dDAVP and BEVA therapy inhibits osteosarcoma progression without overt toxicity. The study supports further evaluation of dDAVP as an adjuvant therapy in osteosarcoma. Guideline-Based Recommendations
Diagnosis
Utilize AVPR2 expression as a prognostic marker in osteosarcoma. Management
Consider the combination of dDAVP and BEVA for enhanced antiangiogenic therapy in osteosarcoma. Monitoring & Follow-up
Assess histopathological markers of tumor aggressiveness during treatment. Risks
Monitor for potential adverse effects associated with antiangiogenic therapies. Patient & Prescribing Data
Patients diagnosed with osteosarcoma, particularly those with high AVPR2 expression.
dDAVP may serve as a complementary agent to improve the efficacy of BEVA in osteosarcoma treatment.
Clinical Best Practices
Integrate multi-targeted approaches to disrupt tumor angiogenesis in osteosarcoma. Utilize established safety profiles of repurposed drugs like dDAVP for accelerated clinical implementation. Related Resources & Content
